Skip to content
The Nexus
DossierENTITY

Argenx

Coverage of Argenx in the Nexus archive.

Earliest in view: Jul 27 · 07:26 UTCMost recent: Aug 21 · 06:27 UTC
Co-mentioned in this coverage
Europeplace1Atlanticplace1Biotechtopic1Stockstopic1Forte Biosciencesorganization1Vyvgarttopic1Dallasplace1Belgiumplace1
Recent coverage
  • BUSINESSAug 21 · 06:27 UTCBLOOMBERG
    Europe Has Its Own Biotech Star as Argenx Soars on Trial Success

    Europe is highlighted as having its own 'Biotech Star,' exemplified by Argenx's stock soaring following successful trials. Overall, the article notes that it has been a big week for biotech stocks on both sides of the Atlantic.

  • BUSINESSJul 27 · 07:26 UTCSTAT NEWS
    STAT+: Argenx to buy Forte Biosciences for $2.2B

    Argenx agreed to acquire Forte Biosciences for $2.2 billion in cash, valuing the Dallas-based company at $77 per share, a 41% premium. The deal aims to expand Argenx's immunology pipeline, leveraging its success with the autoimmune drug Vyvgart.